• Positive net cash flow from operating activities of $1.5 million
• Cash and cash equivalents of $18.5 million at quarter end
• Continued investment in R&D and intellectual property

SomnoMed Limited, a leading provider of medical devices for sleep-disordered breathing, has reported its quarterly cash flow results for the period ended 31 December 2024. The company generated positive net cash flow from operating activities of $1.5 million, with receipts from customers totaling $26.6 million. SomnoMed continued to invest in research and development, as well as intellectual property, with payments of $0.4 million and $0.2 million, respectively. The company's cash and cash equivalents position remained strong, standing at $18.5 million at the end of the quarter. SomnoMed also maintained its financing facilities, with a total of $1.0 million in loan facilities, all of which were drawn at the end of the quarter. The company's quarterly cash flow report provides a transparent view of its financial performance and ongoing investments in support of its business objectives.